Introducing
Your new presentation assistant.
Refine, enhance, and tailor your content, source relevant images, and edit visuals quicker than ever before.
Trending searches
N Articles
> 50
> 20
> 10
> 5
> 1
CEACAM6_Cancer
CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND (Cancer [tiab])
Query
Query Link
https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28Cancer+%5Btiab%5D%29&sort=pubdate
Results
202 Articles
(Mar 24, 2022)
Highlights
_Colorectal Cancer
CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("Colorectal Cancer" [tiab] OR "Colon Cancer" [tiab] OR "Colon Carcinoma" [tiab])
Query
Query Link
https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28%22Colorectal+Cancer%22+%5Btiab%5D+OR+%22Colon+Cancer%22++%5Btiab%5D++OR+%22Colon+Carcinoma%22+%5Btiab%5D%29&sort=pubdate
Results
69 Articles
(Mar 24, 2022)
Highlights
CEACAM6_Pancreatic Cancer
CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("Pancreatic cancer" [tiab] OR "Pancreatic carcinoma" [tiab])
Query
Query Link
https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28%22Pancreatic+cancer%22+%5Btiab%5D+OR+%22Pancreatic+carcinoma%22+%5Btiab%5D%29&sort=pubdate
Results
31 Articles
(Mar 24, 2022)
Highlights
CEACAM6_Lung Cancer
CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("Lung Cancer" [tiab] OR "Lung Adenocarcinoma" [tiab] OR "Lung Carcinoma" [tiab])
Query
Query Link
https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28%22Lung+Cancer%22+%5Btiab%5D+OR+%22Lung+Adenocarcinoma%22+%5Btiab%5D+OR+%22Lung+Carcinoma%22+%5Btiab%5D%29&sort=pubdate
Results
35 Articles
(Mar 24, 2022)
Highlights
CEACAM6_Leukemia
Query
CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND (Leukemia [tiab])
Query Link
https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28Leukemia+%5Btiab%5D%29&sort=pubdate
Results
35 Articles
(Mar 24, 2022)
Highlights
CEACAM6_IBD
Query
CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("Inflammatory bowel disease" [tiab] OR "Crohn's Disease" [tiab])
Query Link
https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28%22Inflammatory+bowel+disease%22+%5Btiab%5D+OR+%22Crohn%27s+Disease%22+%5Btiab%5D%29&sort=pubdate
Results
30 Articles
(Mar 24, 2022)
Highlights
CEACAM6_Breast Cancer
Query
CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("Breast Cancer" [tiab] OR "Breast Carcinoma" [tiab])
Query Link
https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28%22Breast+Cancer%22+%5Btiab%5D+OR+%22Breast+Carcinoma%22+%5Btiab%5D%29&sort=pubdate
Results
28 Articles
(Mar 24, 2022)
Highlights
CEACAM6_Ovarian Cancer
Query
CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("Ovarian Cancer" [tiab] OR "Ovarian Carcinoma" [tiab])
Query Link
https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28%22Ovarian+Cancer%22+%5Btiab%5D+OR+%22Ovarian+Carcinoma%22+%5Btiab%5D%29&sort=pubdate
Results
5 Articles
(Mar25, 2022)
Highlights
CEACAM6_GI Cancer
CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("Gastric Cancer" [tiab] OR "Gastric Carcinoma" [tiab], "Gastric Adenocarcinoma" [tiab] OR "Gastrointestinal Cancer" [tiab])
Query
Query Link
https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28%22Gastric+Cancer%22+%5Btiab%5D+OR+%22Gastric+Carcinoma%22+%5Btiab%5D%2C+%22Gastric+Adenocarcinoma%22+%5Btiab%5D+OR+%22Gastrointestinal+Cancer%22+%5Btiab%5D%29&sort=pubdate
Results
2 Articles
(Mar25, 2022)
Highlights
CEACAM6_Thyroid Cancer
CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("Thyroid Carcinoma" [tiab] OR "Thyroid Cancer" [tiab])
Query
Query Link
https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28%22Thyroid+Carcinoma%22+%5Btiab%5D+OR+%22Thyroid+Cancer%22+%5Btiab%5D%29&sort=pubdate
Results
3 Articles
(Mar25, 2022)
Highlights
CEACAM6_Cystic Fibrosis
CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("Cystic fibrosis" [tiab])
Query
https://pubmed.ncbi.nlm.nih.gov/20047061/
Query Link
Results
1 Article
(Mar25, 2022)
Highlights
CEACAM6_Head & Neck Cancer
CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("Head and Neck cancer" [tiab] OR "Head and Neck Carcinoma" [tiab])
Query
https://pubmed.ncbi.nlm.nih.gov/23021083/
Query Link
Results
1 Article
(Mar25, 2022)
Highlights
CEACAM6_Osteosarcoma
CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND (Osteosarcoma [tiab])
Query
https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28Osteosarcoma+%5Btiab%5D%29&sort=pubdate
Query Link
Results
2 Articles
(Mar25, 2022)
Highlights
CEACAM6_Asthma
CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND (Asthma [tiab])
Query
https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28Asthma+%5Btiab%5D%29&sort=pubdate
Query Link
Results
4 Articles
(Mar25, 2022)
https://pubmed.ncbi.nlm.nih.gov/28275137/
- In lungs of patients with Asthma expressed in both airway epithelial cells and in neutrophils.
- The abundance of neutrophils is not changed in Asthma patients, but the proportion of neutrophils expressing CEACAM6 is increased.
Highlights
CEACAM6_Laryngeal Cancer
CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("Laryngeal cancer" [tiab] OR "Laryngeal carcinoma" [tiab] OR "Laryngeal squamous cell carcinoma" [tiab])
Query
https://pubmed.ncbi.nlm.nih.gov/30094098/
Query Link
Results
1 Article
(Mar25, 2022)
Highlights
CEACAM6_Pregnancy
Query
CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND (Pregnancy [tiab])
Query Link
https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28Pregnancy+%5Btiab%5D%29&sort=pubdate
Results
14 Articles
(Mar 24, 2022)
Highlights
CEACAM6_Myeloma
Query
CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("myeloma" [tiab])
Query Link
https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28%22myeloma%22+%5Btiab%5D%29&sort=pubdate
Results
9 Articles
(Mar 24, 2022)
Highlights
CEACAM6_Cholangiocarcinoma
Query
CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND (Cholangiocarcinoma [tiab])
Query Link
https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28Cholangiocarcinoma+%5Btiab%5D%29&sort=pubdate
Results
7 Articles
(Mar 24, 2022)
Highlights
N Articles
> 50
> 20
> 10
> 5
> 1
Association with poor survivial/prognosis
Marker for early detection in blood
As a cancer stem cell marker
_Colorectal Cancer
CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("Colorectal Cancer" [tiab] OR "Colon Cancer" [tiab] OR "Colon Carcinoma" [tiab]) AND (biomarker [tiab] OR biomarkers [tiab] OR diagnostic [tiab] OR diagnosis [tiab] OR prognostic [tiab] OR prognosis [tiab])
Query
https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28%22Colorectal+Cancer%22+%5Btiab%5D+OR+%22Colon+Cancer%22+%5Btiab%5D+OR+%22Colon+Carcinoma%22+%5Btiab%5D%29+AND+%28biomarker+%5Btiab%5D+OR+biomarkers+%5Btiab%5D+OR+diagnostic+%5Btiab%5D+OR+diagnosis+%5Btiab%5D+OR+prognostic+%5Btiab%5D+OR+prognosis+%5Btiab%5D%29&sort=date
Query Link
Results
15 Articles
(Sept 05, 2022)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058681/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800633/
Association with poor survivial/prognosis
Marker for differentiation of malignant vs benign tumors
_Pancreatic Cancer
CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("Pancreatic cancer" [tiab] OR "Pancreatic carcinoma" [tiab]) AND (biomarker [tiab] OR biomarkers [tiab] OR diagnostic [tiab] OR diagnosis [tiab] OR prognostic [tiab] OR prognosis [tiab])
Query
https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28%22Pancreatic+cancer%22+%5Btiab%5D+OR+%22Pancreatic+carcinoma%22+%5Btiab%5D%29+AND+%28biomarker+%5Btiab%5D+OR+biomarkers+%5Btiab%5D+OR+diagnostic+%5Btiab%5D+OR+diagnosis+%5Btiab%5D+OR+prognostic+%5Btiab%5D+OR+prognosis+%5Btiab%5D%29&sort=date
Query Link
Results
18 Articles
(Sept 05, 2022)
https://www.por-journal.com/articles/10.3389/pore.2021.1609868/full
https://www.mdpi.com/2075-1729/11/6/542/htm
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0113023
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1356989/
https://www.spandidos-publications.com/ijo/43/3/877
Associated with poor survivial/prognosis
_Lung Cancer
CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("Lung Cancer" [tiab] OR "Lung Adenocarcinoma" [tiab] OR "Lung Carcinoma" [tiab]) AND (biomarker [tiab] OR biomarkers [tiab] OR diagnostic [tiab] OR diagnosis [tiab] OR prognostic [tiab] OR prognosis [tiab])
Query
https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28%22Lung+Cancer%22+%5Btiab%5D+OR+%22Lung+Adenocarcinoma%22+%5Btiab%5D+OR+%22Lung+Carcinoma%22+%5Btiab%5D%29+AND+%28biomarker+%5Btiab%5D+OR+biomarkers+%5Btiab%5D+OR+diagnostic+%5Btiab%5D+OR+diagnosis+%5Btiab%5D+OR+prognostic+%5Btiab%5D+OR+prognosis+%5Btiab%5D%29&sort=date
Query Link
Results
11 Articles
(Sept 05, 2022)
https://www.sciencedirect.com/science/article/pii/S193652332200064X?via%3Dihub
https://www.spandidos-publications.com/10.3892/ol.2021.12510
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339813/
This study evaluated the diagnostic ability of CD66c in lung adenocarcinoma-associ- ated malignant pleural effusions (LA-MPEs) and compared it with other known tumour markers.
https://link.springer.com/article/10.1007/s00428-014-1688-1
_Leukemia
CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND (Leukemia [tiab]) AND (biomarker [tiab] OR biomarkers [tiab] OR diagnostic [tiab] OR diagnosis [tiab] OR prognostic [tiab] OR prognosis [tiab])
Query
https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28Leukemia+%5Btiab%5D%29+AND+%28biomarker+%5Btiab%5D+OR+biomarkers+%5Btiab%5D+OR+diagnostic+%5Btiab%5D+OR+diagnosis+%5Btiab%5D+OR+prognostic+%5Btiab%5D+OR+prognosis+%5Btiab%5D%29&sort=date
Query Link
Results
16 Articles
(Sept 05, 2022)
https://bmccancer.biomedcentral.com/track/pdf/10.1186/1471-2407-5-38.pdf
As a cancer stem cell marker
Early detection
Associated with poor survivial/prognosis
_Breast Cancer
CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("Breast Cancer" [tiab] OR "Breast Carcinoma" [tiab] OR "Breast tumor" [tiab] OR "breast tumors" [tiab]) AND (biomarker [tiab] OR biomarkers [tiab] OR diagnostic [tiab] OR diagnosis [tiab] OR prognostic [tiab] OR prognosis [tiab] OR sensitivity [tiab] OR specificity [tiab] OR "positive predictive value" [tiab] OR "negative predictive value" [tiab] OR "odds ratio" [tiab] OR "fold change" [tiab] OR "association" [tiab] OR "associated" [tiab])
Query
Query Link
https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28%22Breast+Cancer%22+%5Btiab%5D+OR+%22Breast+Carcinoma%22+%5Btiab%5D+OR+%22Breast+tumor%22+%5Btiab%5D+OR+%22breast+tumors%22+%5Btiab%5D%29+AND+%28biomarker+%5Btiab%5D+OR+biomarkers+%5Btiab%5D+OR+diagnostic+%5Btiab%5D+OR+diagnosis+%5Btiab%5D+OR+prognostic+%5Btiab%5D+OR+prognosis+%5Btiab%5D+OR+sensitivity+%5Btiab%5D+OR+specificity+%5Btiab%5D+OR+%22positive+predictive+value%22+%5Btiab%5D+OR+%22negative+predictive+value%22+%5Btiab%5D+OR+%22odds+ratio%22+%5Btiab%5D+OR+%22fold+change%22+%5Btiab%5D+OR+%22association%22+%5Btiab%5D+OR+%22associated%22+%5Btiab%5D%29&sort=date
Results
20 Articles
(Sept 05, 2022)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7191048/
https://aacrjournals.org/clincancerres/article/14/2/405/196147/Carcinoembryonic-Antigen-Cell-Adhesion-Molecule-6
Overall, gene-based aggregation analyses revealed that rare PTVs in CEACAM6, CEACAM7, and CEACAM8 are associated with European American breast cancer risk, and rare PTVs in CEACAM7 are associated with breast cancer risk in African Americans (Table 5).
EA = European American
AA = African American
PTV = protein truncating variant
https://www.frontiersin.org/articles/10.3389/fgene.2021.702889/full
https://aacrjournals.org/clincancerres/article/12/15/4773/188827/Expression-of-Carcinoembryonic-Antigen-Cell
N Articles
> 50
> 20
> 10
> 5
> 1
CEACAM6_Granulocytes
CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("granulocytes" [tiab] OR "granulocyte" [tiab])
Query
Query Link
https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28%22granulocytes%22+%5Btiab%5D+OR+%22granulocyte%22+%5Btiab%5D%29&sort=date&size=200&show_snippets=off
Results
66 Articles
(Dec 05, 2021)
Results Link
https://pubmed.ncbi.nlm.nih.gov/?term=34467524+27626616+23941132+23630956+22768164+19334050+18056392+17909799+17517873+15541289+15488142+14707113+12379336+11994468+11847104+10666389+10475238+9862166+9714468+9427723+8890209+8664114+7594554+7591230+7735161+8018919+8119777+7736546+8104998+7690348+8099907+7683969+8508798+1458480+1431566+1640165+1323111+1592535+1370882+1370907+2050678+1849127+1824544+1778210+2174725+2208113+1701159+2178978+2306228+1690879+2154215+2408131+2261596+2475724+2474516+3211435+3211433+3128509+3320743+3568003+2420267+3882113+6724739+6713409+6987861+92357&show_snippets=off&sort=date&size=200
Evaluation of the CEACAM6 literature associated with Granulocytes indicates that its expression on this cell type is well-documented. It is however not restricted to Granulocytes as it is also expressed in normal and malignant tissues. One article also indicates that its expression in normal bone marrow is restricted to myeloid cells and expressed at particularly high levels in promyelocytes [9714468]
Highlights
https://pubmed.ncbi.nlm.nih.gov/3320743/
https://pubmed.ncbi.nlm.nih.gov/9714468/
CEACAM6 = CD66c
Early description of CECAM6 and CEACAM8 in granulocytes (presumably)
CEACAM6_Neutrophils
Query
CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("neutrophil" [tiab] OR "neutrophils" [tiab])
Query Link
https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28%22neutrophil%22+%5Btiab%5D+OR+%22neutrophils%22+%5Btiab%5D%29&show_snippets=off&sort=date&size=200
Results
43 Articles
(Dec 30, 2021)
https://pubmed.ncbi.nlm.nih.gov/?term=34847408+34707398+34639156+34467524+34217339+32019805+29760215+29518953+28292985+28275137+23630956+22064717+21470677+20560140+19077207+18552205+17561254+15541289+12005421+11590190+11333142+10754323+10496313+9427723+9332316+9218600+8977287+8699114+8776764+8645267+8542935+7594554+8543346+7897228+8104998+7689841+8099907+1359882+1431566+1640165+1378450+1712645+1694660&show_snippets=off&sort=date&size=200
Results Link
https://pubmed.ncbi.nlm.nih.gov/8543346/
https://pubmed.ncbi.nlm.nih.gov/8699114/
https://pubmed.ncbi.nlm.nih.gov/11590190/
Highlights
CEACAM6_Intestinal Epithelial Cells
Query
CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("intestinal epithelial cell*" [tiab])
Query Link
https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Bti%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Bti%5D+OR+CD66c+%5Bti%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28%22granulocytes%22+%5Btiab%5D+OR+%22granulocyte%22+%5Btiab%5D%29&show_snippets=off&sort=date&size=200
Results
26 Articles
(Dec 05-, 2021)
https://pubmed.ncbi.nlm.nih.gov/?term=23941132+18056392+17909799+15541289+15488142+12379336+10666389+10475238+9862166+9714468+9427723+8890209+8664114+7591230+7735161+8018919+8119777+7736546+8104998+7690348+8099907+7683969+8508798+1458480+1431566+1640165+1323111+1592535+1370882+1370907+2050678+1849127+1824544+1778210+2174725+2208113+1701159+2178978+2306228+1690879+2154215+2408131+2261596+2475724+2474516+3211435+3211433+3128509+3320743+3568003+2420267+3882113+6724739+6713409+6987861+92357&show_snippets=off&sort=date&size=200
Results Link
CEACAM6 is recruited to the surface of mucosa cells, including intestinal epithelial cells, by pathogen and possesses immunomodulatory properties (promoting the epithelial cell immune response to pathogens) [28292985]
https://pubmed.ncbi.nlm.nih.gov/28292985/
https://pubmed.ncbi.nlm.nih.gov/24898815/
https://pubmed.ncbi.nlm.nih.gov/25706391/
Highlights
https://pubmed.ncbi.nlm.nih.gov/24326999/
CEACAM6_T-cells
CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND (T-cell [tiab] OR T-cells [tiab] OR T-lymphocytes [tiab] OR T-lymphocyte [tiab])
Query
Query Link
https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28T-cell+%5Btiab%5D+OR+T-cells+%5Btiab%5D+OR+T-lymphocytes+%5Btiab%5D+OR+T-lymphocyte+%5Btiab%5D%29&show_snippets=off&sort=date&size=200
Results
27 Articles
(Dec 30, 2021)
https://pubmed.ncbi.nlm.nih.gov/?term=34707398+34467524+33838601+33674603+32849600+32368831+31797958+30546940+28521477+28292985+27284373+26271985+25872647+24040308+23603913+19637360+20063526+17909799+17561254+17057200+16485257+11994468+9714468+9218600+7808000+2185585+6837309&sort=date&size=200&show_snippets=off
Results Link
https://pubmed.ncbi.nlm.nih.gov/27284373/
https://pubmed.ncbi.nlm.nih.gov/23603913/
Highlights
###_---
---
Query
----
Query Link
Results
- Articles
(Nov --, 2020)
---
Results Link
Highlights
###_---
---
Query
----
Query Link
Results
- Articles
(Nov --, 2020)
---
Results Link
Highlights
###_---
---
Query
----
Query Link
Results
- Articles
(Nov --, 2020)
---
Results Link
Highlights
###_---
---
Query
----
Query Link
Results
- Articles
(Nov --, 2020)
---
Results Link
Highlights
###_---
---
Query
----
Query Link
Results
- Articles
(Nov --, 2020)
---
Results Link
Highlights
###_---
---
Query
---
Query Link
Results
-- Articles
(Nov --, 2020)
---
Results Link
Highlights
> 10
> 5
Expression
(FC over control)
> 2
> 1.5
GSE100150
<-1.5
<-2
Expression
(FC over control)
<-5
<-10
This box plot shows levels of abundance of CEACAM6 RNA measured by microarrays in the blood of human subjects, including patients with Influenza infection and healthy controls. The fold change between the two groups is 5.74, p=0.018 (two-tailed heteroscedastic t-test).
http://cd2k.gxbsidra.org/dm3/miniURL/view/Nd
This box plot shows levels of abundance of CEACAM6 RNA measured by microarrays in the blood of human subjects, including patients with Respiratory Syncytial Virus (RSV) and uninfected controls. The fold change between the two groups is 17.2, p<0.001 (two-tailed heteroscedastic t-test).
http://cd2k.gxbsidra.org/dm3/miniURL/view/NV
This box plot shows levels of abundance of CEACAM6 RNA measured by microarrays in the blood of human subjects, including pregnant women and non pregnant controls. Fold change between the two groups is 2.00, p=0.0069 (two-tailed heteroscedastic t-test).
http://cd2k.gxbsidra.org/dm3/miniURL/view/Ne
This box plot shows levels of abundance of CEACAM6 RNA measured by microarrays in the blood of human subjects, including patients with Tuberculosis (TB) and uninfected controls. The fold change between the two groups is 1.3, p=0.5 (two-tailed homoscedastic t-test).
http://cd2k.gxbsidra.org/dm3/miniURL/view/NX
This box plot shows levels of abundance of CEACAM6 RNA measured by microarrays in the blood of human subjects, including patients with sepsis and uninfected controls. Fold change between the two groups is 4.96, p<0.01 (two-tailed heteroscedastic t-test).
http://cd2k.gxbsidra.org/dm3/miniURL/view/Nb
This box plot shows levels of abundance of CEACAM6 RNA measured by microarrays in the blood of human subjects, including patients with acute Staphylococcus aureus (S. aureus) infection and uninfected controls. Fold change between the two groups is 12.3, p<0.0001 (two-tailed heteroscedastic t-test).
http://cd2k.gxbsidra.org/dm3/miniURL/view/Na
This box plot shows levels of abundance of CEACAM6 RNA measured by microarrays in the blood of human subjects, including patients with Systemic Lupus Erythematosus (SLE) and healthy controls. Fold change between the two groups is 2.24 p=0.14 (two-tailed homoscedastic t-test). NS= not significant.
http://cd2k.gxbsidra.org/dm3/miniURL/view/NZ
This box plot shows levels of abundance of CEACAM6 RNA measured by microarrays in the blood of human subjects, including patients with Kawasaki Disease and healthy controls. The fold change in Kawasaki patients over healthy controls is 6.08, p=0.010 (two-tailed heteroscedastic t-test).
http://cd2k.gxbsidra.org/dm3/miniURL/view/NS
This box plot shows levels of abundance of CEACAM6 RNA measured by microarrays in the blood of human subjects, including patients with Systemic onset Juvenile Idiopathic Arthritis and controls. Fold change between the two groups is 5.14, p=0.018 (two-tailed heteroscedastic t-test).
http://cd2k.gxbsidra.org/dm3/miniURL/view/NY
This box plot shows levels of abundance of CEACAM6 RNA measured by microarrays in the blood of human subjects, including patients with multiple sclerosis and controls. Fold change between the two groups is 1.09, p=0.76 (NS, two-tailed heteroscedastic t-test).
http://cd2k.gxbsidra.org/dm3/miniURL/view/NO
"Subjects enrolled in the MS cohort had an established diagnosis of relapsing-remitting MS, separately confirmed by an experienced MS neurologist (JTP), exhibited no other health conditions, and had received no treatment(s) for MS, including corticosteroids, for at least 3 months prior to blood collection" (Altman et al. 2022: https://www.nature.com/articles/s41467-021-24584-w)
This box plot shows levels of abundance of CEACAM6 RNA measured by microarrays in the blood of human subjects, including patients with Juvenile Dermatomyositis and healthy controls. The fold change between the two groups is 1.70, p=0.57 (two-tailed heteroscedastic t-test).
http://cd2k.gxbsidra.org/dm3/miniURL/view/NL
This box plot shows levels of abundance of CEACAM6 RNA measured by microarrays in the blood of human subjects, including liver transpant recipients under mainenance immunosuppressive therapy and healthy controls. The fold change between the two groups is 3.46, p<0.001 (two-tailed heteroscedastic t-test).
Enrollment criteria included age 17–65 years, having received a liver transplant under maintenance immunosuppression therapy. Subjects in this cohort had not received an acute or chronic rejection diagnosis at the time of sampling [https://www.nature.com/articles/s41467-021-24584-w]
http://cd2k.gxbsidra.org/dm3/miniURL/view/Nc
This box plot shows levels of abundance of CEACAM6 RNA measured by microarrays in the blood of human subjects, including patients with Melanoma and healthy controls. Fold change between the two groups is 3.7, p=0.064 (NS, two-tailed heteroscedastic t-test).
http://cd2k.gxbsidra.org/dm3/miniURL/view/NM
Enrollment criteria included age 21–75 years, stage M1a, M1b, M1c biopsy proven metastatic melanoma patients with measurable metastatic lesions by physical examination or scans, acceptable CBC and blood chemistry results, adequate hepatic and renal function, and no active CNS metastatic disease [https://www.nature.com/articles/s41467-021-24584-w]
NS
This box plot shows levels of abundance of CEACAM6 RNA measured by microarrays in the blood of human subjects, including patients with Chronic Obstructive Pulmonary Disease (COPD) and healthy controls. The fold change between the two groups is 1.4, p=0.32 (two-tailed homoscedastic t-test). NS= not significant.
Enrollment criteria included age over 40 years, no history of concurrent lung cancer, chest surgery, or chronic lung diseases other than COPD (e.g., sarcoidosis, fibrosis, etc.). Participants had no history of allergies or asthma and at the time of initial recruitment had not received oral or systemic corticosteroids during the previous 6 weeks; volunteers were enrolled from three clinics within the Texas Medical Center in Houston (TX, USA) [https://www.nature.com/articles/s41467-021-24584-w]
http://cd2k.gxbsidra.org/dm3/miniURL/view/NI
NS
This box plot shows levels of abundance of CEACAM6 RNA measured by microarrays in the blood of human subjects, including patients with B-cell deficiency and healthy controls. Fold change between the two groups is 1.97, p=0.3 (two-tailed heteroscedastic t-test). NS= not significant.
http://cd2k.gxbsidra.org/dm3/miniURL/view/NJ
This box plot shows levels of abundance of CEACAM6 RNA measured by microarrays in the blood of human subjects, including patients with HIV infection and healthy controls. The fold change between the two groups is 2.14, p=0.026 (two-tailed heteroscedastic t-test).
Blood samples were obtained from adult patients diagnosed with HIV infection. At enrollment patients were verified as acute Fiebig stages 4–6 (plasma RNA + , third-generation EIA+, Western blot indeterminant or + ) [https://www.nature.com/articles/s41467-021-24584-w]
http://cd2k.gxbsidra.org/dm3/miniURL/view/NK
This violin plot shows fold change in abundance of CEACAM6 RNA measured by RNA sequencing in the blood of human subjects across different disease cohorts, compared to their respective control subjects.
Reference: Altman, Rinchai et al. Nat Comms 2021
Source: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE100150;
Plot: https://chart-studio.plotly.com/create/?fid=dchaussabel%3A132
Interactive version with values expressed as counts: http://cd2k.gxbsidra.org/dm3/miniURL/view/NH
> 10
> 5
Expression
(FC over control)
> 2
> 1.5
GSE30101
<-1.5
<-2
Expression
(FC over control)
<-5
<-10
Levels of CEACAM6 transcript abundance in blood exposed to immune stimuli in vitro. The box plot represents transcript abundance levels for the CEACAM6 gene in blood samples obtained from four healthy donors, cultivated for 6 hours at 37°C in the presence of pathogens, as well as pathogen-derived and host-derived immune stimuli (HKAL = heat-killed Acholeplasma laidlawii, HKLP = heat-killed Legionella pneumophila, HKSA = heat-killed Staphylococcus aureus, Flu = live influenza A virus, RSV = live respiratory syncytial virus).
For details, see original work by Obermoser et al., Immunity, 2013
GEO deposition: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE30101
Plot: https://plotly.com/~dchaussabel/173/
GSE60424
> 30
> 10
Expression
(FC over control)
> 5
CEACAM6GSE60424
> 1.5
<-1.5
<-5
Expression
(FC over control)
<-10
<-30
This box plot shows levels of abundance of CEACAM6 RNA measured by RNA sequencing in neutrophils, monocytes, B-cells, CD4 T-cells, CD8 T-cells and NK cells purified from the blood of human subjects, including patients with ALS, Type 1 Diabetes, Multiple Sclerosis (immediately before and 24 hours after initiation of beta interferon therapy) or sepsis and healthy controls. Values are normalized to the median calculated across all conditions.
Reference: Linsley et al. https://pubmed.ncbi.nlm.nih.gov/25314013/
Source: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE60424;
Plot: https://chart-studio.plotly.com/create/?fid=dchaussabel%3A132
Interactive version with values expressed as counts: http://cd2k.gxbsidra.org/dm3/miniURL/view/NH
> 20
> 10
Expression
(FC over median)
> 5
> 2
> 50
> 20
Literature
(N articles)
> 5
> 0
ISG15 [tw] OR "ISG15 Ubiquitin Like Modifier" [tw] OR "Interferon-stimulated gene 15" [tw] OR "IFN-induced 15-kDa protein" [tw] OR IFI-15K [tw] OR "Ubiquitin Cross-Reactive Protein" [tw] OR "Ubiquitin-Like Protein ISG15" [tw] OR (HUCRP [tw] AND "Cross-Reactive Protein" [tw]) OR G1P2 [tw] OR IP17 [tw] OR (UCRP [tw] AND "Cross-Reactive Protein" [tw]) OR "Interferon-Induced 17-KDa/15-KDa Protein" [tw] OR "Interferon-Stimulated Protein, 15 Kda" [tw] OR "Interferon-Induced 17 Kda Protein" [tw] OR IFI15 [tw] OR IMD38 [tw] NOT review [pt] AND (monocyte OR monocytes)
This box plot shows levels of abundance of ISG15 RNA measured by RNAseq in neutrophils, monocytes, B-cells, CD4 T-cells, CD8 T-cells and NK cells purified from the blood of human subjects, including patients with ALS, Type 1 Diabetes, Multiple Sclerosis (immediately before and 24 hours after initiation of beta interferon therapy) or sepsis and healthy controls.
Box plots can be generated either in Excel or using Plotly (online tool)
https://chart-studio.plotly.com/create/
https://plotly.com/~dchaussabel/122/
https://docs.google.com/presentation/d/18G45CIp29PqwUYGaAmrb_m-PWLXsjuaPVLqGXD8xY0s/edit?usp=sharing
This box plot shows levels of abundance of ISG15 RNA measured by RNAseq in neutrophils purified from the blood of human subjects, including patients with ALS, Type 1 Diabetes, Multiple Sclerosis (immediately before and 24 hours after initiation of beta interferon therapy) or sepsis and healthy controls.
This box plot shows levels of abundance of ISG15 RNA measured by RNAseq in neutrophils, monocytes, B-cells, CD4 T-cells, CD8 T-cells and NK cells purified from the blood of human subjects, including patients with ALS, Type 1 Diabetes, Multiple Sclerosis (immediately before and 24 hours after initiation of beta interferon therapy) or sepsis and healthy controls.
Download button
http://cd2k.gxbsidra.org/dm3/miniURL/view/Mk
1) Access interactive figure
This box plot shows levels of abundance of CEACAM6 RNA measured by RNA sequencing in neutrophils, monocytes, B-cells, CD4 T-cells, CD8 T-cells and NK cells purified from the blood of human subjects, including patients with ALS, Type 1 Diabetes, Multiple Sclerosis (immediately before and 24 hours after initiation of beta interferon therapy) or sepsis and healthy controls. Values are normalized to the median calculated across all conditions.
Reference: Linsley et al. https://pubmed.ncbi.nlm.nih.gov/25314013/
Source: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE60424;
Plot: https://chart-studio.plotly.com/create/?fid=dchaussabel%3A132
Interactive version with values expressed as counts: http://cd2k.gxbsidra.org/dm3/miniURL/view/NH
?
+
> 20
> 5
Expression
(FC over control)
> 2
> 1.5
<-1.5
<-2
Expression
(FC over control)
<-5
<-20
?
-
N Articles
> 5
> 2
1
https://www.sciencedirect.com/science/article/pii/S0197458014007052
https://europepmc.org/article/pmc/pmc4715677
Table 5. Differentially-expressed genes between mild and severe cases of IPF.
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0037708
https://www.degruyter.com/document/doi/10.1515/jpm-2013-0082/html
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058681/
https://www.nature.com/articles/s41598-022-15547-2
https://www.nature.com/articles/s41591-020-0944-y
https://www.frontiersin.org/articles/10.3389/fimmu.2021.694243/full
https://onlinelibrary.wiley.com/doi/full/10.1111/jcmm.16773
https://jlb.onlinelibrary.wiley.com/doi/full/10.1002/JLB.6MA0720-015RR?casa_token=g31iFpT5XSYAAAAA%3AChPeV--nP42JTPZJLgi2JMRYuJGrY-wbHHqLzRsCbh-gVPc6Orrdb-tRaNfGQRt9IDEH0WWKBgOmgIU
https://www.degruyter.com/document/doi/10.1515/jpm-2013-0082/html
Summary
This gene encodes a protein that belongs to the carcinoembryonic antigen (CEA) family whose members are glycosyl phosphatidyl inositol (GPI) anchored cell surface glycoproteins. Members of this family play a role in cell adhesion and are widely used as tumor markers in serum immunoassay determinations of carcinoma. This gene affects the sensitivity of tumor cells to adenovirus infection. The protein encoded by this gene acts as a receptor for adherent-invasive E. coli adhesion to the surface of ileal epithelial cells in patients with Crohn's disease. This gene is clustered with genes and pseudogenes of the cell adhesion molecules subgroup of the CEA family on chromosome 19. [provided by RefSeq, Apr 2014]
https://www.ncbi.nlm.nih.gov/gene/4680
Cell surface glycoprotein that plays a role in cell adhesion and tumor progression (PubMed:2803308, PubMed:2022629, PubMed:1378450, PubMed:8776764, PubMed:11590190, PubMed:10910050, PubMed:14724575, PubMed:16204051). Intercellular adhesion occurs in a calcium- and fibronectin-independent manner (PubMed:2022629, PubMed:16204051). Mediates homophilic and heterophilic cell adhesion with other carcinoembryonic antigen-related cell adhesion molecules, such as CEACAM5 and CEACAM8 (PubMed:2803308, PubMed:2022629, PubMed:8776764, PubMed:11590190, PubMed:16204051). Heterophilic interaction with CEACAM8 occurs in activated neutrophils (PubMed:8776764). Plays a role in neutrophil adhesion to cytokine-activated endothelial cells (PubMed:1378450). Plays a role as an oncogene by promoting tumor progression; positively regulates cell migration, cell adhesion to endothelial cells and cell invasion (PubMed:16204051). Also involved in the metastatic cascade process by inducing gain resistance to anoikis of pancreatic adenocarcinoma and colorectal carcinoma cells (PubMed:10910050, PubMed:14724575)
https://www.uniprot.org/uniprot/P40199
https://journals.sagepub.com/doi/10.1177/17588359211072621
"CEACAM6 is a member of the carcinoembryonic antigen molecules, widely distributed in epithelial and myeloid cells.12 It acts as an intercellular cell adhesion molecule to maintain tissue architecture through interactions with other CEACAM proteins.13 It has been described as a modulator of cancer progression due to its
effects on differentiation and cell growth, resistance to anoikis, treatment resistance, invasiveness and metastasis.14 Indeed, CEACAM6 is upregulated preferentially at the apical/luminal membranes of many tumors.12 This effect was first observed in leukemia15 and subsequently in colorectal,16 pancreatic,17 gastric,18 lung,19 and many others.20–23 Recently, CEACAM6 has been suggested as a target for different cancer immunotherapies given the fact that its membrane expression is highly specific of tumor cells.11 In models of non-small cell lung cancer, different antibodies against CEACAM6 block cell viability, invasion, and migration through inhibition of Src/FAK phosphorylation.24 In models of pancreatic adenocarcinoma, the use of monoclonal antibodies (mAb) against this protein sensitizes cells to cytotoxicity using secondary antibodies.25 A different immunotherapy strategy is the development of humanized single-chain antibody variable fragments (scFv) based on CEACAM6,26 or specific CEACAM6-single domain antibodies (sdAB)
that have demonstrated to inhibit cell growth.27 CEACAM6 has also been used to create antibody–drug conjugates (ADC), using a tubulin
inhibitor as a payload, showing preclinical efficacy in pancreatic cancer.28"
https://www.tandfonline.com/doi/epub/10.1080/2162402X.2021.2008110?needAccess=true
https://en.wikipedia.org/wiki/CEACAM6
▼ Description
Carcinoembryonic antigen (CEA; 114890) is one of the most widely used tumor markers in serum immunoassay determinations of carcinoma. An apparent lack of absolute cancer specificity for CEA probably results in part from the presence in normal and neoplastic tissues of antigens that share antigenic determinants with the 180-kD form of CEA (Barnett et al., 1988). For background information on the CEA family of genes, see CEACAM1 (109770).
▼ Cloning and Expression
Barnett et al. (1988) presented sequences of a 'normal crossreacting antigen' (NCA) and showed that CEA and NCA, although closely related in sequence, are structurally and probably functionally distinct.
Using immunohistochemical analysis, Scholzel et al. (2000) showed that human CEACAM6 was expressed in granulocytes and epithelial cells in various organs. In squamous epithelial cells, CEACAM6 displayed nonpolarized cell surface localization and cytoplasmic localization, but in simple epithelia, CEACAM6 was present on the apical surface. CEACAM6 exhibited apical expression throughout colon development and was found in the upper half of developing crypts. CEACAM6 expression correlated with expression of CD95 (FAS; 134637) and with apoptosis at the table region of normal colon, but CEACAM6 was absent from highly proliferating cells at the base of colonic crypts.
▼ Mapping
By in situ hybridization, Willcocks et al. (1989) mapped NCA to 19q13 in the same region as CEA. The localization was supported by studies with a somatic cell hybrid cell line. By a combination of Southern blot analysis and in situ hybridization, Inazawa et al. (1989) localized the gene to 19q13.2.
▼ Gene Function
In 15 patients with Crohn disease (CD; see 266600) and 9 controls, Barnich et al. (2007) found that adherent-invasive E. coli (AIEC) adhesion was dependent on type 1 pili expression on the bacterial surface and on CEACAM6 expression on the apical surface of ileal epithelial cells. CEACAM6 acted as a receptor for AIEC adhesion and was upregulated in the ileal mucosa of CD patients compared to colonic mucosa or to controls. In vitro studies showed increased CEACAM6 expression in cultured intestinal epithelial cells after IFN-gamma (147570) or TNF-alpha (191160) stimulation and after infection with AIEC.
By desensitizing neutrophils to stimulation by various combinations of anti-CD66 antibodies, Skubitz and Skubitz (2008) showed that the 4 neutrophil CEACAMs, including CEACAM6, had significant independent signaling functions. However, the results suggested that the CEACAMs may also act in combination, with CEACAM1 having a unique role.
By screening a panel of pancreatic cancer cell lines for sensitivity to adenovirus, followed by differential gene expression analysis between sensitive and insensitive cells, Wang et al. (2009) found that CEACAM6 expression correlated with the sensitivity of tumor cells to the virus. CEACAM6 blocked adenovirus trafficking to the nucleus through the SRC (190090) pathway, interfering with cancer cell cytoskeleton and reducing adenoviral infection. Knockdown of CEACAM6 with small interfering RNA significantly increased adenovirus replication and antitumor efficacy of oncolytic adenovirus in a mouse xenograft tumor model. Wang et al. (2009) concluded that CEACAM6 is a tumor-associated gene that affects the ability of cancer cells to be infected with adenovirus.
Mouse neutrophils do not bind the human-restricted pathogen Neisseria gonorrhoeae. Sarantis and Gray-Owen (2012) showed that introducing any of the gonorrheal Opa-binding human neutrophil CEACAMs into a murine neutrophil cell line allowed binding and entry of Neisseria. CEACAM1 and CEACAM6 both bound and allowed entry of the bacterium, but they mediated little neutrophil activation. In contrast, uptake via CEACAM3 (609142) induced an oxidative burst and intracellular granule release comparable to that seen during human neutrophil infection. Coexpression of CEACAM3 with either CEACAM1 or CEACAM6 potentiated CEACAM3-dependent responses. Sarantis and Gray-Owen (2012) concluded that, although CEACAMs have different functions in neutrophils, they cooperate during gonorrheal infection. Their findings implicated CEACAM3 in the neutrophil innate response to neisserial infection.
https://www.omim.org/entry/163980?search=CEACAM6&highlight=ceacam6
https://www.genecards.org/cgi-bin/carddisp.pl?gene=BPI
https://www.genecards.org/cgi-bin/carddisp.pl?gene=CEACAM6
https://www.genecards.org/cgi-bin/carddisp.pl?gene=CEACAM8
https://www.genecards.org/cgi-bin/carddisp.pl?gene=DEFA1
https://www.genecards.org/cgi-bin/carddisp.pl?gene=DEFA3
https://www.genecards.org/cgi-bin/carddisp.pl?gene=DEFA4
https://www.genecards.org/cgi-bin/carddisp.pl?gene=ELANE
https://www.genecards.org/cgi-bin/carddisp.pl?gene=LTF
https://www.genecards.org/cgi-bin/carddisp.pl?gene=CTSG
https://www.genecards.org/cgi-bin/carddisp.pl?gene=OLFM4
https://ayllonbe.github.io/modulesV3/modules_results_html/M10.4.json.html
CEACAM6_degranulation
CEACAM6 [tiab] OR "CEA Cell Adhesion Molecule 6" [tiab] OR CD66c [tiab] OR (NCA [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen Related Cell Adhesion Molecule 6" [tiab] OR "Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6" [tiab] OR ("Normal Cross-Reacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR ("Non-Specific Crossreacting Antigen" [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) OR (CEAL [tiab] AND (Carcinoembryonic OR CEACAM6 OR CD66c)) NOT review [pt] AND ("granules" OR "degranulation" [tiab])
Query
Query Link
https://pubmed.ncbi.nlm.nih.gov/?term=CEACAM6+%5Btiab%5D+OR+%22CEA+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+CD66c+%5Btiab%5D+OR+%28NCA+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen+Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%22Carcinoembryonic+Antigen-Related+Cell+Adhesion+Molecule+6%22+%5Btiab%5D+OR+%28%22Normal+Cross-Reacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28%22Non-Specific+Crossreacting+Antigen%22+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+OR+%28CEAL+%5Btiab%5D+AND+%28Carcinoembryonic+OR+CEACAM6+OR+CD66c%29%29+NOT+review+%5Bpt%5D+AND+%28%22granules%22+OR+%22degranulation%22+%5Btiab%5D%29&show_snippets=off&sort=pubdate&size=200
Results
9 Articles
(Feb 08, 2022)
https://pubmed.ncbi.nlm.nih.gov/?term=34639156+18056392+8890209&show_snippets=off&sort=pubdate&size=200
Results Link
https://pubmed.ncbi.nlm.nih.gov/8543346/
Highlights
Neutrophil activation
Acumenta Biotech
Literature Lab
http://www.acumenta.com/literature-lab-1
Red = strong association
Orange = moderate association
No result found for this module
No result found for this module
RcisTarget
https://motoufiq.github.io/DC_Gen3_Module_Analysis/
RcisTarget Reference Web page
https://pubmed.ncbi.nlm.nih.gov/28991892/
https://www.bioconductor.org/packages/release/bioc/html/RcisTarget.html
https://drinchai.shinyapps.io/BloodGen3Module/